Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Cytokinetics, IncorporatedNASDAQ: CYTK

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $104.4M rose 58.8% year over year, ahead of the +53.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.

Context

  • Selling, general & admin amounted to 322.9% of revenue in FY2025, down 842.6 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 15 analysts of $1.34B (+370.5%) for the fiscal year ending Dec 2026, a step up from the +32.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$104.4M-0.5% QoQ
Last fiscal yearDec 2025
$284.27M+32.0% YoY
LTMJun 2026
$370.47M+53.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.8%+396.8%+338.0 pp
1 year+32.0%+370.5%+338.5 pp
3-year CAGR+16.9%+199.0%+182.1 pp
5-year CAGR+133.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
284.27M USD
Year-over-year change
+32.0%
4-year CAGR
+30.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 selling, general & admin of $370.47M is the highest of the 3 companies compared; the peer median is $32.69M.
  • Its year-over-year change of +53.0% is the highest of 2, against a peer median of -4.5%.
  • Selling, general & admin amounts to 522.1% of revenue for CYTK, versus a peer median of 5380.6%.
CYTK Competitors Peer median
Selling, General & Admin for CYTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$370.47M +53.0%+16.9%522.1%
RNAAtrium Therapeutics, Inc.FY2025$41.68M ——223.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M -4.5%+3.4%10537.3%
KARDKardigan, Inc.—— ———
Peer median (excluding CYTK) $32.69M-4.5%+3.4%5380.6%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.